285 related articles for article (PubMed ID: 31471838)
21. Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Liu D; Chang L; Hao Q; Ren X; Liu P; Liu X; Wei Y; Wang M; Wu H; Kang H; Lin S
J Cancer Res Clin Oncol; 2024 May; 150(5):285. PubMed ID: 38814494
[TBL] [Abstract][Full Text] [Related]
22. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
[TBL] [Abstract][Full Text] [Related]
23. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
25. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
27. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
Kuroi K; Toi M; Ohno S; Nakamura S; Iwata H; Masuda N; Sato N; Tsuda H; Kurosumi M; Akiyama F
Breast Cancer; 2015 Sep; 22(5):486-95. PubMed ID: 24338638
[TBL] [Abstract][Full Text] [Related]
29. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
Shang Y; Wang X; Liu Y; Cheng W; Duan Y; Fang Z; Liu J; Kong F; Wang T; Yu T; Hu A; Zhang J; Zhang H; Li M; Rong Z; Li Y; Shakila SS; Li X; Feng J; Ma F; Guo B
Breast Cancer; 2024 Jul; 31(4):684-694. PubMed ID: 38643430
[TBL] [Abstract][Full Text] [Related]
30. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China.
Zhao S; Wang Y; Zhou A; Liu X; Zhang Y; Zhang J
PeerJ; 2024; 12():e17492. PubMed ID: 38827304
[TBL] [Abstract][Full Text] [Related]
33. Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.
Baulies S; Cusidó M; González-Cao M; Tresserra F; Fargas F; Rodríguez I; Úbeda B; Ara C; Fábregas R
J Obstet Gynaecol; 2015; 35(5):485-9. PubMed ID: 25383894
[TBL] [Abstract][Full Text] [Related]
34. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
35. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
[TBL] [Abstract][Full Text] [Related]
37. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
38. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
[TBL] [Abstract][Full Text] [Related]
40. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
